Treatment of diabetes mellitus: implications of the use of oral agents.
Rao
S V
SV
Department of Medicine, Duke University Medical Center, Durham, NC, 27710, USA.
Bethel
M A
MA
Feinglos
M N
MN
D020909:Acarbose / Q000008:administration & dosage; D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D015994:Incidence; D007328:Insulin / Q000097:blood; D008687:Metformin / Q000008:administration & dosage; D013453:Sulfonylurea Compounds / Q000008:administration & dosage; D015996:Survival Rate
D020909:Acarbose; D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D008687:Metformin; D013453:Sulfonylurea Compounds; C057619:glimepiride